US2003013713A1PendingUtilityA1

Compounds as PDE IV and TNF-inhibitors

54
Priority: Jul 28, 1993Filed: Jul 29, 2002Published: Jan 16, 2003
Est. expiryJul 28, 2013(expired)· nominal 20-yr term from priority
A61P 37/06A61P 43/00A61P 37/08A61P 3/10A61P 7/12A61P 31/12A61P 31/00A61P 31/04A61P 25/16A61P 33/06A61P 33/00A61P 25/28A61P 29/00A61P 31/18A61P 27/16A61P 25/00A61P 35/02C07D 213/75A61P 1/04C07C 235/56C07D 213/65C07D 213/79C07D 401/12C07C 2603/66A61P 11/02C07D 213/81C07C 237/30C07D 213/89C07C 2601/08A61P 17/04A61P 19/00C07D 213/69C07C 255/60A61P 11/00C07D 409/12A61P 17/02C07C 217/58A61P 11/08C07C 43/247A61P 13/12C07D 417/12A61P 11/06C07D 213/70C07C 327/48A61P 17/00A61P 17/06C07C 2603/64C07D 213/82A61P 19/08A61P 19/02C07D 413/12
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound of formula I  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is lower alkyl optionally substituted by one or more of halo, cycloalkyl or cycloalkenyl;  
 R 2  is alkyl, alkenyl or alkynyl each optionally substituted by one or more of halo, cycloalkyl or cycloalkenyl; or cycloalkyl or cycloalkenyl each optionally substituted by one or more of halo, methylidene or alkyl; or optionally substituted cyclothioalkyl consisting of a non-aromatic monocyclic or multicyclic ring system of 3 to about 10 ring atoms wherein at least one of the ring atoms is sulphur and the other ring atoms are carbon and the substituted cyclothioalkyl is substituted by one or more halo, or any ring sulphur atom is optionally oxidised to the corresponding S-oxide or S,S-dioxide; or optionally substituted cyclothioalkenyl consisting of a non-aromatic monocyclic or multicyclic ring system of 3 to about 10 ring atoms wherein at least one of the ring atoms is sulphur, the other ring atoms are carbon and the ring system contains a carbon-carbon double bond and the substituted cyclothioalkenyl is substituted by one or more halo or any ring sulphur atoms is optionally oxidised to the corresponding S-oxide or S,S-dioxide;  
 R 3  is optionally substituted aryl or heteroaryl, wherein the substituted aryl or substituted heteroaryl group is substituted by one or more substituents which may be the same or different and are selected from alkyl, aryl, aralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkyloxy, carboxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarboxyl, aryloxycarbonyl, aralkyloxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, alkylthio, arylthio, aralkylthio, Y 1 Y 2 N—, Y 1 Y 2 NCO— or Y 1 Y 2 NSO 2 —, where Y and Y are independently hydrogen, alkyl, aryl, and aralkyl;  
 Q 1, Q   2  and Q 3  are independently nitrogen, CX or CH, provided that at least one of Q 1 , Q 2  and Q 3  is other than CH;  
 Z, Z 1  and Z 2  are independently oxygen or sulfur;  
 Z 3  is —CH═CH—, —CZCH 2 —, —CZ-CZ—, —CH 2 —NH—, —CH 2 —O—, —CX 2 —O—, —CH 2 —S—, —CH 2 —SO 2 — or —CZNH—; and  
 X is halo;  
 or N-oxide thereof or a pharmaceutically acceptable salt thereof; with the proviso that R 1 Z 1  and R 2 Z 2  cannot both represent methoxy.  
 
     
     
         2 . The compound according to  claim 1  wherein 
 R 2  is alkyl optionally substituted by one or more halo, cycloalkyl or cycloalkenyl; cycloalkyl or cycloalkenyl each optionally substituted by one or more of halo, methylidene or alkyl; or optionally substituted cyclothioalkyl consisting of a non-aromatic monocyclic or multicyclic ring system of 3 to about 10 ring atoms wherein at least one of the ring atoms is sulphur and the other ring atoms are carbon and the substituted cyclothioalkyl is substituted by one or more halo, or any ring sulphur atom is optionally oxidised to the corresponding S-oxide or S,S-dioxide;  
 R 3  is phenyl, substituted phenyl or azaheteroaryl;  
 Q 1  and Q 2  are independently nitrogen, CX or CH, provided that at least one of Q 1  and Q 2  is other than CH;  
 Q 3  is CH; and  
 Z 3  is —CZCH 2 — or —CZNH—.  
 
     
     
         3 . The compound according to  claim 2  wherein 
 R 1  is methyl or difluoromethyl;  
 R 2  is isopropyl, cyclopropylmethyl, cyclopentyl, trinorbornyl, trinorbornenyl, tricyclo[2.2.1.0 2.6. ]heptanyl and tetrahydrothiophenyl;  
 Z 1  is oxygen or sulphur;  
 Z 2  is oxygen; and  
 Z 3  is —COCH 2 — or —CONH—.  
 
     
     
         4 . The compound according to  claim 1  wherein Q 1  and Q 2  are independently nitrogen, CX or CH, and at least one of Q 1  and Q 2  is nitrogen or CX, and Q 3  is CH.  
     
     
         5 . The compound according to  claim 4  wherein CX is preferably CF.  
     
     
         6 . The compound according to  claim 1  wherein Q 1  is CX, and Q 2  and Q 3  are CH; Q 2  is CX, and Q 1  and Q 3  are CH; Q 1  is N, and Q 2  and Q 3  are CH; Q 2  is N, and Q 1  and Q 3  are CH; or Q 1  and Q 2  are N, and Q 3  are CH.  
     
     
         7 . The compound according to  claim 6  wherein CX is preferably CF.  
     
     
         8 . The compound according to  claim 1  wherein Q 2  is nitrogen or CF.  
     
     
         9 . The compound according to  claim 1  wherein independently Q 1 , Q 2  or Q 3  is N-oxide or R 3  is azaheterocyclyl having an imine moiety thereof as an N-oxide.  
     
     
         10 . The compound according to  claim 1  wherein Q 1  and Q 3  are CH, and Q 2  is an N-oxide.  
     
     
         11 . The compound according to  claim 1  wherein R 3  is phenyl substituted on the 2-position or on both the 2- and 6-positions.  
     
     
         12 . The compound according to  claim 1  wherein R 3  is heteroaryl substituted on one or both of the positions adjacent to the position of R 3  that is attached to Z 3 .  
     
     
         13 . The compound according to  claim 1  wherein R 3  is azaheteroaryl substituted on one or both, more preferably on both, of the positions adjacent to a position of R 3  that is attached to Z 3 .  
     
     
         14 . The compound according to  claim 13  wherein R 3  is a 3,5-dihalo-pyrid-4-yl.  
     
     
         15 . The compound according to  claim 14  wherein 3,5-dihalo-1-oxido-4-pyridinium.  
     
     
         16 . The compound according to  claim 1  wherein Z 2  is —CZNH— or —CZCH 2 —.  
     
     
         17 . The compound according to  claim 16  wherein Z is oxygen.  
     
     
         18 . The compound according to  claim 1  wherein Z 1  and Z 2  are oxygen, or Z 1  is sulfur and Z 2  is oxygen.  
     
     
         19 . The compound according to  claim 18  wherein Z 1  and Z 2  are oxygen.  
     
     
         20 . The compound according to  claim 1  wherein Z 1  is oxygen.  
     
     
         21 . The compound according to  claim 1  wherein R 1  is lower alkyl optionally substituted by one or more halo.  
     
     
         22 . The compound according to  claim 21  wherein the substitutition is on a position of R 1  that is attached to Z 1 .  
     
     
         23 . The compound according to  claim 1  wherein R 2  is lower alkyl, cycloalkyl or cyclothioalkyl optionally substituted by one or more halo.  
     
     
         24 . The compound according to  claim 23  wherein the substitutition is on a position of R 2  that is attached to Z 1 .  
     
     
         25 . The compound according to  claim 23  wherein R 2  is cyclothioalkyl substituted on a position of R 2  that is attached to Z 1  or on a position adjacent to the thio moiety of the cyclothioalkyl.  
     
     
         26 . The compound according to  claim 1  wherein R 2  is isopropyl, cyclopropylmethyl, cyclopentyl, trinorbornyl, trinorbornenyl, tricyclo[2.2.1.0 2.6. ]heptanyl and tetrahydrothiophenyl.  
     
     
         27 . The compound according to  claim 1  wherein R 2  is cyclothioalkyl oxidized to the corresponding S-oxide or S,S-dioxide.  
     
     
         28 . The compound according to  claim 1  wherein R 1  is lower alkyl optionally substituted by halo; and R 2  is isopropyl, cyclopropylmethyl, cyclopentyl, trinorbornyl, trinorbornenyl, tricyclo[2.2.1.0 2.6. ]heptanyl and tetrahydrothiophenyl.  
     
     
         29 . The compound according to  claim 1  which is: 
 N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-difluorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-chloro-6-fluorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-trifluoromethylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,4,6-trichlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dibromophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-chloro-6-methylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-fluorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-phenyl-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-methoxyphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-chlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-chlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(4-methoxyphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dimethylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-methylthiophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-bromophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-methoxycarbonylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-aminosulfonylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-benzoylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-cyanophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,5-dichlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-methylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-nitrophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-dimethylaminophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-acetylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-hydroxyphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(4-chloropyrid-3-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-pyrid-2-yl-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-pyrazin-2-yl-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-pyrimidin-2-yl-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-methylpyrid-2-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-pyrid-3-yl-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-chloropyrid-2-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-chloropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-pyrid-4-yl-3-cyclopentyl oxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dimethylisoxazol-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dibromopyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dimethylpyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide,  
 N-(2,6-dichloro-4-cyanophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-methoxycarbonylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,3,5-trifluoropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-ethoxycarbonylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-nitrophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-difluoropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-bromo-5-chloropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,4,6-trifluorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-methoxyphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(4,6-dichloropyrimid-5-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,3,5,6-tetrafluoropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dichloro-2,6-difluoropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(5-cyano-3-methylisothiazol-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-carbamoylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-chloro-2,5,6-trifluoropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(4-nitrophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3-methyl-5-bromoisothiazol-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dimethylisothiazol-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-difluorophenyl)-3-cyclohexyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-difluorophenyl)-3-butoxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-difluorophenyl)-3-propoxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dichloropyrid-4-yl)-3-cyclopent-2-enyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dichloropyrid-4-yl)-3-cyclopent-3-enyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-methylsulfonylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2-chlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxy(thiobenzamide);  
 N-(3,5-dichloropyrid-4yl)-3-cyclopentyloxy-6-fluoro-4-methoxy(thiobenzamide);  
 N-(3,5-dichloropyrid-4yl)-3-cyclopentyloxy-6-fluoro-4-methoxy(thiobenzamide);  
 N-(2,6-dichloro-4-acetylaminophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-hydroxymethylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(2,6-dichloro-4-formylphenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide; sodium salt of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 (±)N-(3,5-dichloropyrid-4-yl)-3-exonorbornyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dichloropyrid-4-yl)-2-fluoro-5-isopropyloxy-4-methoxybenzamide;  
 (±)N-(3,5-dichloropyrid-4-yl)-2-fluoro-4-methoxy-5-(tricyclo[2.2.1.0]hept-2-yloxy)benzamide hemihydrate;  
 N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-difluoromethoxy-6-fluorobenzamide  
 N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-2-fluoro-5-isopropyloxybenzamide;  
 2-(3,5-dichloropyrid-4-yl)-1-(3-cyclopentyloxy-6-fluoro-4-methoxyphenyl)ethanone;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-2-fluoro-5-isopropyloxy-4-methoxybenzamide;  
 (±)N-(3,5-dichloro-1-oxido-4-pyridinio)-3-exo(8,9,10-trinorbornyloxy)-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-3-cyclopentyloxy-6-fluoro-4-methoxybenzamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-3-cyclopentyloxy-4-difluoromethoxy-6-fluorobenzamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-difluoromethoxy-2-fluoro-5-isopropyloxybenzamide;  
 2-(3,5-Dichloro-1-oxido-4-pyridinio)-1-(3-cyclopentyloxy-6-fluoro-4-methoxyphenyl)ethanone;  
 5-cyclopentyloxy-N-(3,5-dichloropyrid-4-yl)-6-methoxynicotinamide;  
 N-(2,6-dichlorophenyl)-5-cyclopentyloxy-6-methoxynicotinamide;  
 5-cyclopentyloxy-N-(3,5-dimethylisoxazol-4-yl)-6-methoxynicotinamide  
 5-cyclopentyloxy-N-(3,5-difluoropyrid-4-yl)-6-methoxynicotinamide  
 6-cyclopentyloxy-N-(3,5-dichloropyrid-4-yl)-5-methoxypyridine-2-carboxamide;  
 1-(5-cyclopentyloxy-6-methoxypyridin-3-yl)-2-(3,5-dichloropyrid-4-yl)ethanone;  
 5-cyclopentyloxy-N-(3,5-dichloro-4-pyridyl)-6-methylthionicotinamide;  
 N-(3,5-dichloro-4-pyridyl)-5-isopropyloxy-6-methylthionicotinamide;  
 2-(3,5-dichloro-4-pyridyl)-1-(5-isopropyloxy-6-methylthio-3-pyridyl)ethanone;  
 1-(5-cyclopentyloxy-6-methoxypyrid-3-yl)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone hemihydrate;  
 (±)-N-(3,5-dichloropyrid-4-yl)-6-methoxy-5-exo-(8,9,10-trinorborn-5-en-2-yloxy)nicotinamide;  
 (±)-N-(3,5-dichloropyrid-4-yl)-6-methoxy-5-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)nicotinamide monohydrate;  
 N-(3,5-dichloropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-difluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-chloro-6-fluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-trifluoromethylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,4,6-trichlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dibromophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-chloro-6-methylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2. carboxamide;  
 N-(2,6-dichlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-fluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-phenyl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-methoxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-chlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-chlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(4-methoxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dimethylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-methylthiophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-bromophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-methoxycarbonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-aminosulfonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-benzoylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-cyanophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,5-dichlorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-methylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-nitrophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-dimethylaminophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-acetylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2-hydroxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(4-chloropyrid-3-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-pyrid-2-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-pyrazin-2-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-pyrimidin-2-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-methylpyrid-2-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-pyrid-3-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-chloropyrid-2-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-chloropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-pyrid-4-yl-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dimethylisoxazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dibromopyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dimethylpyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dichloro-4-cyanophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dichloro-4-methoxycarbonylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N— (2,3, 5-trifluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N— (2,6-dichloro-4-ethoxycarbonyl phenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dichloro-4-nitrophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-difluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-bromo-5-chloropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,4,6-trifluorophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dichloro-4-methoxyphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(4,6-dichloropyrimid-5-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,3,5,6-tetrafluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dichloro-2,6-difluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(5-cyano-3-methylisothiazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(2,6-dichloro-4-carbamoylphenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-chloro-2,5,6-trifluoropyrid-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(4-nitrophenyl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3-methyl-5-bromoisothiazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dimethylisothiazol-4-yl)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-methoxypyridine-2-carboxamide;  
 1-(4-cyclopentyloxy-5-methoxypyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;  
 (±)-N-(3,5-difluoropyrid-4-yl)-6-methoxy-5-exo(8,9,10-trinorborn-2-yloxy)nicotinamide;  
 (±)-N-(3,5-dichloropyridin-4-yl)-6-methoxy-5-exo(8,9,10-trinorborn-2-yloxy)nicotinamide;  
 (±)-N-(3,5-dichloropyrid-4-yl)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)pyridine-2-carboxamide;  
 (±)-N-(3,5-difluoropyrid-4-yl)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)pyridine-2-carboxamide hydrate;  
 (±)-N-(3,5-dichloropyridin-4-yl)-5-methoxy-4-(tetrahydrothiophen-3-yloxy)pyridine-2-carboxamide;  
 N-(3,5-dichloropyridin-4-yl)-4-cyclopropylmethoxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dichloropyridin-4-yl)-4-isopropyloxy-5-methoxypyridine-2-carboxamide;  
 (±)-N-(3,5-dichloro-1-oxido-4-pyridinio)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]-hept-2-yloxy)pyridine-2-carboxamide;  
 (±)-N-(3,5-difluoro-1-oxido-4-pyridinio)-5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]-hept-2-yloxy)pyridine-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-isopropyloxy-5-methoxypyridine-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopropylmethoxy-5-methoxypyridine-2-carboxamide hemihydrate;  
 (±)-N-(3,5-dichloro-1-oxido-4-pyridinio)-5-methoxy-4-(tetrahydrothiophen-3-yloxy)pyridine-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopropylmethoxy-5-methoxy-1-oxidopyridinium-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-isopropyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide;  
 1-(5-methoxy-4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)pyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;  
 (±)-1-(5-methoxy-4-(tetrahydrothiophen-3-yloxy)pyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;  
 1-(4-(tricyclo[2.2.1.0. 2.6. ]hept-2-yloxy)-5-methoxypyridin-2-yl)-2-(3,5-dichioro-1-oxido-4-pyridinio)ethanone;  
 N-(3,5-dichloropyridin-4-yl)-4-cyclopropylmethoxy-5-methoxy-1-oxidopyridinium-2-carboxamide;  
 N-(3,5-dichloropyridin-4-yl)-4-isopropyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide;  
 N-(3,5-dichloropyridin-4-yl)-4-cyclopentyloxy-5-methoxy-1-oxidopyridinium-2-carboxamide hemihydrate;  
 N-(2-chlorophenyl)-3-cyclopentyloxy-6-fluoro-4-methoxybenzylamine;  
 N-(2-chlorophenyl)-4-cyclopentyloxy-5-methoxy-2-aminomethylpyridine;  
 trans-2-(2,6-dichlorophenyl)-1-(3-cyclopentyloxy-6-fluoro-4-methoxyphenyl)ethene;  
 trans-1-(3-cyclopentyloxy-6-fluoro-4-methoxyphenyl)-2-(2,6-difluorophenyl)ethene;  
 trans-2-(2,6-dichlorophenyl)-1-(4-cyclopentyloxy-5-methoxypyrid-2-yl)ethene;  
 trans-1-(4-cyclopentyloxy-5-methoxypyrid-2-yl)-2-(2,6-difluorophenyl)ethene;  
 1-[(3-cyclopentyloxy-6-fluoro-4-methoxy)phenyl]-2-(pyrid-4-yl)ethane-1,2-dione;  
 1-(4-cyclopentyloxy-5-methoxypyrid-2-yl)-2-(pyrid-4-yl)ethane-1,2-dione;  
 N-(3,5-dichloropyrid-4-yl)-5-cyclopentyloxy-6-methoxypyridazine-3-carboxamide;  
 N-(3,5-dichloropyridin-4-yl)-4-cyclopentyloxy-5-difluoromethoxypyridine-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-difluoromethoxypyridine-2-carboxamide;  
 N-(3,5-dichloropyrid-4-yl)-4-cyclopentyloxy-5-difluoromethoxy-1-oxidopyridium-2-carboxamide;  
 N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopentyloxy-5-difluoromethoxy-1-oxidopyridium-2-carboxamide;  
 1-(5-difluoromethoxy-4-(cyclopentyloxy)pyridin-2-yl)-2-(3,5-dichloropyridin-4-yl)ethanone;  
 1-(5-difluoromethoxy-4-(cyclopentyloxy)-1-oxido-2-pyridium)-2 (3,5-dichloropyridin-4-yl)ethanone;  
 1-(5-difluoromethoxy-4-(cyclopentyloxy)pyridin-2-yl)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone;  
 1-(5-difluoromethoxy-4-(cyclopentyloxy)-1-oxido-2-pyridium)-2-(3,5-dichloro-1-oxido-4-pyridinio)ethanone;  
 N-(3,5-dichloropyrid-4-yl)-5,6-dimethoxypyridazine-3-carboxamide; and  
 1-(5,6-dimethoxypyridazine-3-pyridium)-2-(3,5-dichloropyridin-4-yl)ethanone.  
 
     
     
         30 . A pharmaceutical composition comprising a pharmaceutiocally acceptable amount of the compound of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         31 . A method for treating a disease state capable of being modulated by inhibiting TNF comprising administering to a patient suffering from said disease state an effective amount of the compound of  claim 1 .  
     
     
         32 . The method of  claim 31  wherein the disease state is an inflammatory disease or autoimmune disease.  
     
     
         33 . The method of  claim 31  wherein the disease state is selected from the group consisting of joint inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis and osteoarthritis, sepsis, septic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, asthma, bone resorption diseases, reperfusion injury, graft vs host reaction, allograft rejection malaria, myalgias, HIV, AIDS, cachexia, Crohn's disease, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type I diabetes mellitus, psoriasis, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukemia.  
     
     
         34 . The method of  claim 31  wherein the disease state is joint inflammation.  
     
     
         35 . A method for treating a disease state capable of being modulated by inhibiting production of cyclic AMP phosphodiesterase comprising administering to a patient suffering from said disease state an effective amount of the compound of  claim 1 .  
     
     
         36 . The method of  claim 35  wherein the disease state is a pathological condition associated with a function of cyclic AMP phophodiesterase, eosinophil accumulation or a function of the eosinophil.  
     
     
         37 . The method of  claim 36  wherein the pathological condition is asthma, atopic dermatitis, urticaria, allergic rhinitis, psoriasis, rheumatic arthritis, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome, diabetes insipidus, keratosis, dermatitis, cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, cardiac arrest, stroke and intermittent claudication.  
     
     
         38 . The method of  claim 36  wherein the pathological condition is asthma.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.